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Aims Coronary microvascular smooth muscle cells (SMCs) respond to luminal pressure by developing myogenic tone
(MT), a process integral to the regulation of microvascular perfusion. The cellular mechanisms underlying poor




Intramyocardial coronary micro-arteries (IMCAs) isolated from human and pig right atrial (RA) appendage and left
ventricular (LV) biopsies were studied using pressure myography combined with confocal microscopy. All RA- and
LV-IMCAs from organ donors and pigs developed circa 25% MT. In contrast, 44% of human RA-IMCAs from 88
patients with heart valve disease had poor (<10%) MT yet retained cell viability and an ability to raise cytoplasmic
Ca2þ in response to vasoconstrictor agents. Comparing across human heart chambers and species, we found that
based on patient medical history and six tests, the strongest predictor of poor MT in IMCAs was increased expres-
sion of the synthetic marker caldesmon relative to the contractile marker SM-myosin heavy chain. In addition, high
resolution imaging revealed a distinct layer of longitudinally aligned SMCs between ECs and radial SMCs, and we
show poor MT was associated with disruptions in these cellular alignments.
....................................................................................................................................................................................................
Conclusion These data demonstrate the first use of atrial and ventricular biopsies from patients and pigs to reveal that impaired
coronary MT reflects a switch of viable SMCs towards a synthetic phenotype, rather than a loss of SMC viability.
These arteries represent a model for further studies of coronary microvascular contractile dysfunction.
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1. Introduction
Coronary vascular smooth muscle cells (SMCs) exert physiological func-
tions through both contractile and synthetic SMC phenotypes, together
maintaining effective function of the coronary circulation.1,2 Within the
coronary microcirculation, contractile SMCs exert myogenic reactivity
and tone,3,4 which is an important regulator of myocardial perfusion.3–9
Furthermore, contractile SMCs react to vasoactive factors acting directly
on SMCs or via the endothelium, often released and acting in response
to metabolic demand.3–9 In parallel, synthetic SMCs secrete extracellular
matrix components and may increase proliferation and migration during
vessel remodelling, e.g. exercise, pregnancy, or vascular repair.1,2,10 The
role of contractile and synthetic SMCs in intramyocardial coronary
micro-arteries (IMCAs) in patients with no significant coronary ischaemic
disease has not been investigated. Coronary microvascular dysfunction
in the absence of obstructive coronary disease is associated with angina-
like chest pain, heart failure, inflammation, and poor prognosis.11–17
However, the causes of the microvascular dysfunction, in particular poor
myogenic reactivity, in isolated human IMCAs (h-IMCAs) from viable
myocardia are not known, and this knowledge is of prime importance
for myocardial function.
Normal or dysfunctional IMCAs cannot be imaged directly in vivo
due to the technological limitations of modern in vivo imaging,16,18,19
despite the clear need to do so for effective treatment strategies.20
Instead, indexes of microvascular dysfunction are based primarily on
changes in response to vasodilators17,18 or on indirect imaging evalua-
tions, such as myocardial perfusion scans based on myocardial uptake
of contrast dye or radioisotopes.21 The more recent use of pressure
and temperature wires to provide raw values for an index of micro-
vascular resistance are clear advances,22 but do not separate myo-
genic tone (MT) from other influences, such as vascular remodelling
and vasoconstrictors. Instead, h-IMCAs are studied ex vivo, isolated
from human right atrial appendage biopsies (h-RA-IMCAs). These
small coronary arteries and arterioles are myogenically active23–25 and
respond to vasoconstrictors and both endothelium-dependent and -
independent vasodilators.23,24,26 While their function has been studied
for decades, little is known regarding their structure and how this
influences function. Histological images of micro-arteries within fixed-
tissue slices are available,27 and fluorescence imaging of h-IMCAs from
right atrium have been reported,6,24,28 but these all lack paired assess-
ment of MT and vascular reactivity. Perhaps most importantly, there
are no ex vivo functional data from human left ventricular IMCAs (h-
LV-IMCAs). At present no cardiac surgery allows sampling of the large
biopsies (1 cm2) required for IMCA reactivity studies and sourcing
organ donor biopsies for this purpose has not been achieved. The pig
is arguably the most appropriate non-primate alternative29 with
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A synthetic SMC phenotype underlies coronary microvascular contractile dysfunction. The profile of biomarkers for contractile vs. synthetic phenotype strongly
reflects whether an artery can generate MT and therefore contribute to the regulation of coronary blood flow.













existing work based on sub-epicardial arterioles and large epicardial
coronary arteries.7,30–32 However, no data are available using porcine
atrial (p-RA-) or ventricular (p-LV-) IMCAs from fresh biopsies har-
vested at clinical standards.
The goal of this study was to use a sequence of conventional and
newly established tests of SMC viability to identify pathways associated
with poor MT of h-IMCAs from non-ischaemic myocardium.
2. Materials and methods
In brief, with fully expanded details available in the Supplementary mate-
rial online.
2.1 Human study design
2.1.1 Right atrial appendage surgical study participants
We enrolled 88 patients (aged >_25 and <_80 years) with no typical ob-
structive coronary disease and with valvular disease requiring either aor-
tic valve replacement (AVR) or mitral valve repair/replacement (MVR)
or both (AVRþMVR) undergoing elective or urgent cardiac surgery.
Exclusion criteria are outlined in Table 1.
2.1.1.1 Consenting and confidentiality. Informed consent was
obtained under and by the protocol No. 07Q160738 and No.
11SC0140. Any data information passed on to the Oxford Laboratory
was anonymized. Any lab assay was carried out under blind conditions
with respect to patient risk profile. The study fully complied with the
Data Protection Act.
2.1.1.2 Study settings. The study was set up in Oxford and extended
to Bristol, where all the patients were recruited at the Bristol Heart
Institute (BHI). The University Hospital Bristol NHS Foundation Trust
sponsored the study in Bristol (Sponsor Lock code: 48676/124568/1/
50). The trial was initially approved in 2012 by the Oxford Research
Ethics Committee and extended to the Bristol site (Trust study No: CS/
2012/4200; REC Reference No: 10/H0606/36) and amended in 2015.
RA biopsy samples from recruited patients were transported to Oxford
under a material transfer agreement under strict packaging, temperature
regulation (10C), and time-limit conditions. This research complies
with the Helsinki Declaration.
2.1.1.3 Surgical methods. Operations were carried out following stan-
dard protocols for the BHI. Baseline, surgical, and anaesthetic manage-
ment were according to standardized protocols.33 Briefly, after pre-
medication with temazepam, anaesthesia was induced with a combina-
tion of propofol and remifentanil; muscle relaxation was achieved using
vecuronium. Anaesthesia was maintained by infusion of propofol and
remifentanil (5 mg remifentanil to 1 g propofol). Right atrial (RA) biopsy
(1 cm2) was always collected before starting cardiopulmonary bypass
and prompt storage within 5–10 s in the preservation solution on ice
and then couriered from Bristol to Oxford where they were assessed
within 2–4 h following collection (Figure 1).
2.1.2 Left ventricle biopsies from organ donors
Human heart tissue (Newcastle) was provided by The Newcastle
Institute of Transplantation Tissue Biobank, 17/NE/0022, Research
Ethics Committee North East-Newcastle and North Tyneside 1
Research Ethics Committee.
2.1.2.1 Patient details. Females aged 56, 63, and 71 years. Left ventric-
ular (LV) biopsies (>1cm2) were collected from the endocardial surface,
and together with RA biopsies were immediately placed in preservation
solution on ice, couriered from Newcastle to Oxford, and assessed
......................................................................................................
Table 1 Patient characteristics and exclusion criteria for
h-RA-IMCAs (n ¼ 88)
n %
Sex (female/male) 29/59 100
Age, year (mean±SD) 63±11 88 100
Cardiac disease Valve disease 88 100
Aortic 51 58
Mitral 37 42
Risk factors Treated hypertension 45 51
Treated hypercholesterolaemia 31 35







Ex-smoker (>1 month)a 40 45


















Exclusion criteria Age <25 years or >80 years





Severely dilated atria (>5.0 cm)




Infection, known HIV, Hepatitis
A, B, C
Cancer or receiving chemotherapy
Immune disease
Ongoing pregnancy
SD, standard deviation; ACE, angiotensin converting enzyme; HIV, human immu-
nodeficiency virus; NYHA, New York Heart Association; CCS, Canadian
Cardiovascular Society.
aCeased smoking at least 1 month before surgery.
























































within 5–8 h following collection. Once the biopsy was removed, the
protocols matched the strict procedures used for the human cardiac
surgery RA biopsies, except the courier time was longer.
2.2 Porcine study design
All the animal procedures were undertaken at the University of Bristol
large animal facilities. All procedures were approved by University of
Bristol Research Ethics committee and performed in accordance with
the Guide for the Care and Use of Laboratory Animals,34 the United
Kingdom Animal (Scientific Procedures) Act, 1986, and conform to the
guidelines from Directive 2010/63/EU of the European Parliament on
the protection of animals used for scientific purposes. Procedural
aspects were as previously reported.35 Briefly, juvenile, 5–6 months old
female Landrace White pigs (weight range 45–75 kg) were subject to
general anaesthesia (pre-medication with ketamine, i.m. 15–20 mg/kg, in-
duction with propofol i.v. 16–20 mg/kg and maintained with isoflurane in
oxygen with the vaporizer set at 2%).
2.2.1 Atrial appendage study
Animals recruited in the study were undergoing cardiac surgery with
CPB procedures (PPL 30/2854) from which RA biopsies were collected
following median sternotomy and IV heparin (target INR >400 s) prior
to CPB.
2.2.2 Left ventricle study
Animals recruited in the study were from within a control group of pigs
undergoing cardiac surgery with CPB procedures (PPL 30/3064 and PPL
7008975) from which LV biopsies from the endocardial surface could be
rapidly collected at termination.
All biopsies were at least 1 cm2. At the completion of each surgical
protocol, and while still under general anaesthesia and full monitoring,
animals underwent median sternotomy to expose the heart, the aorta,
and both superior and inferior vena cava. Euthanasia involved cardiople-
gic arrest using cold (0–4˚C) crystalloid solution in the aortic root after
aortic clamping and concomitant exsanguination via the inferior vena
cava. All porcine biopsies were collected, packed, and promptly cour-
iered to Oxford using the same approach used for human RA and LV
biopsies.
2.3 Human and porcine sample collection,
transfer, and dissection
Once in the laboratory, each human or porcine sample was transferred
to a chilled dissecting dish (10C) containing MOPS buffer, opened and
pinned for dissection of IMCAs from within trabeculae (pectinate or pap-
illary muscle) or the subendocardial tissue, respectively, under magnifica-
tion. For all experiments, IMCAs were cannulated onto glass pipettes
(outer diameter up to 100 mm), and tied with 11/0 sutures (Ethicon).
The temperature was slowly raised to 36.6 ± 0.3C, before pressurizing
arteries to 80 mmHg using a gravity-fed pressure tower. Each IMCA was
longitudinally stretched (final length usually 800–1200 mm), and left to
equilibrate for 60 min. After checking for leaks,36 only IMCAs with <5%
deflation in 1 min, or <5 mL/h were used further. As such, all IMCAs in
the study were first assessed for MT, before assessment of endothelial
cell (EC) function (vasodilation to bradykinin) and/or SMC constriction
(to isotonic KCl). Whilst still pressurized, each artery was then proc-
essed for either live/dead stains, EC/SMC Ca2þ, immunohistochemistry
(phalloidin or phenotype), and/or electron microscopy (EM) as shown in
Figure 1. Within this study, we link the percentage MT generated in each
IMCA to specific SMC tests of viability, with the aim of establishing why
some arteries are no longer able to develop MT.
Figure 1 Experimental protocols. (A) For both human and porcine RA surgical biopsies a purse string suture was positioned around the tip of the append-
age, the specimen excised, and the suture tied off and over sewn. Arrowhead, apex, bar =10 mm. (B, C) Sequence of experimental protocols in ex vivo cannu-
lated arteries from patients with valve disease. Each radiating block in (C) represents one patient; e.g. the single micro-artery studied from the patient
indicated by the asterisk developed >_10% MT and dilated to BK, was imaged for live/dead cells, then fixed for EM, all while cannulated and pressurized to 80
mmHg.































































































2.4 SMC Test 1: functional vascular
reactivity studies
Before testing function, the hydraulic conductivity (an index of vascular
leakiness) of IMCAs was calculated from the volume of fluid leaving the
arterial lumen over 1–5 h at 80 mmHg luminal pressure together with
the arterial length and inner diameter, as previously.36 The first test of
SMC contractile function was to establish the extend of MT that devel-
oped in response to 80 mmHg luminal pressure, relative to the maxi-
mum diameter of arteries. The outcome of this test established how the
experiment then progressed, according to the flow chart depicted in
Figure 1. Only those IMCAs with >_10% MT were considered to pass this
first test, and were used for assessment of endothelium-dependent dila-
tion to bradykinin (0.1 fmol/L to 1 mmol/L). SMC function was further
assessed in a sub-group of arteries, which either passed or failed SMC
Test 1, as the vasoconstriction to 45 mmol/L isotonic KCl (added to the
superfusion). The striking contractile behaviour of h-RA-IMCAs was
depicted by the direction of constriction, whether it was radial (circum-
ferential, to reduce diameter), longitudinal (with no clear change in diam-
eter but clear inward, usually twisting, movement) or both together to
give a ‘concertina-type’ twisting motion. The longitudinal movement
could also be observed as lengthening during dilation, often before the
onset of radial dilation. Hence, both the development and reversal of
MT were assessed to categorize arteries. Interestingly, the structure of
the artery wall could be seen in the transmitted images, and the longitu-
dinal movement was often associated with the presence of abnormal
‘reefs’ of cells within the lumen. Values are the mean ± SEM of n patient
or pig samples, one artery per sample.
2.5 SMC Test 2: 3D structure using
confocal fluorescence microscopy
The high incidence of arteries that failed SMC Test 1 suggested the
SMCs were either not viable or their arrangement was disrupted. We
first tested their arrangement. In SMC Test 2, the orientation of SMCs
was established following fixation of cannulated IMCAs at 80 mmHg, us-
ing 2% (wt/vol) paraformaldehyde for 10 min at 36.6 ± 0.3C, then wash-
ing with phosphate-buffered saline (PBS). Following fluorescence
labelling with phalloidin or antibodies, arteries were imaged while still
cannulated and pressurized to 80 mmHg, z-stacks obtained using a 40
objective (1.15 NA, Olympus). Acquired images were colour-coded us-
ing Imaris software (version 8.0.2, Bitplane). The unexpected presence
of l-SMCs prompted a more detailed investigation aimed at establishing
whether their presence helped, hindered, or had no effect on the ability
to generate MT as shown in SMC Test 1.
2.6 SMC Test 3: 3D structure using EM
SMC Test 2 was taken a step further by performing high resolution imag-
ing to evaluate the cell types present in the arterial wall, and the extent
of homo- and heterocellular cell–cell contacts between them. IMCAs
processed for EM were fixed at the end of functional assessment for MT
and vasomotor responses. Cannulated IMCAs maintained at 80 mmHg
and heated to 36.6 ± 0.3C were fixed, transferred to a vial of buffered
fixative, and fixed overnight before processing for transmission electron
microscopy (TEM) and serial block face SEM. Data were examined and
segmented using Imaris software (version 8.0.2, Bitplane).
2.7 SMC Test 4: cell viability studies
Conventional approaches to test the viability of SMCs (and ECs)
commenced by assessing their ability to uptake and de-esterify the
fluorescent dye calcein AM and by comparing labelling with cell per-
meant and impermeant nuclear dyes.37 Cells were classified as live
(calcein in cytoplasm; nuclei stained with Hoechst 33342 but not PI)
or dead (nuclei stained with both Hoechst 33342 and PI; no calcein);
live cells were expressed as a percentage of all cells in a given image
field. Image z-stacks were colour-coded using Imaris software (ver-
sion 8.0.2, Bitplane).
2.8 SMC Test 5: intracellular Ca2þ studies
The high incidence of arteries that passed SMC Test 4, but not SMC
Test 1, required further investigation. After establishing the vaso-
reactivity of arteries (SMC Test 1), changes in arterial SMC and/or EC
intracellular Ca2þ were imaged using the fluorescent Ca2þ indicator
fluo-8. This relied on viable cells to de-esterify the dye, analogous to
SMC Test 4, but also reported whether Ca2þ influx and release path-
ways were operational, and in the case of human arteries, whether
contraction occurred. To facilitate dye retention in cells experiments
were performed at 31–33C. Agents were added directly to a static
bath, except for KCl, which was rapidly switched to a warmed iso-
tonic KCl solution. Porcine IMCAs retained some MT at 31–33C,
and further contracted to isotonic KCl and caffeine, therefore nifedi-
pine (1 mmol/L) was present to reduce movement, which precluded
the use of KCl in these arteries. Responses to both caffeine and bra-
dykinin, to activate Ca2þ release via ryanodine receptors (RyRs) and
inositol trisphosphate receptors, respectively, were obtained in the
same cells, and these agents were used to distinguish longitudinally
arranged SMCs (l-SMCs) from ECs, which was further confirmed by
the Ca2þ influx in response to depolarization with isotonic KCl.
Values are summarized as the mean ± SEM, with n representing the
number of arteries studied.
2.9 SMC Test 6: contractile phenotype
studies
Neither patient history nor the first five SMC Tests clearly identified
why nearly 50% of arteries did not develop >_10% MT. Some arteries
that appeared viable did not contract, even if SMC Ca2þ signalling
was evident. Therefore, experiments were performed to assess the
phenotype of SMCs in IMCAs within and across species. Importantly,
the contractile and synthetic marker antibody concentrations, online
confocal imaging, and offline image processing were kept as constant
as possible. The image acquisition settings were consistent within the
3D z-stack, allowing intra-artery comparison of radial SMC (r-SMC)
and l-SMC expression of SM-MHC or a-SMA, alongside caldesmon
or vimentin. These settings were then matched as closely as possible
for all arteries studied. Arteries were imaged such that the x–y axis
ran along the length of the artery, which allowed multiple r-SMCs to
be visualized in a given field (up to 30 r-SMCs). Multi-channel image
z-stacks (contractile and synthetic markers, plus nuclei and EC label)
were analysed offline using Imaris software (version 8.0.2, Bitplane).
This allowed counts of individual r-SMCs with greater relative inten-
sity for synthetic vs. contractile markers within their cytoplasm as a
percentage of all r-SMCs visible in the field, providing values for per-
centage synthetic r-SMCs. This approach was considered the most in-
formative and accurate index of relative marker expression within

































































































and between arteries. Separately, to calculate the percentage of cells
expressing caldesmon in r-SMC to l-SMC, the average fluorescence
intensity of lines drawn across either r-SMCs or l-SMCs were used, in
most cases from a plane where both r-SMCs and l-SMCs were clearly
visible and separated. The same lines could be used for both contrac-
tile and synthetic markers within a given image plane. This enabled
both a direct comparison of the same protein between r-SMCs and l-
SMCs, and an indirect comparison between contractile and synthetic
proteins.
2.10 Materials
NaCl, KCl, and D-glucose were purchased from Fisher Scientific
(Loughborough, UK); MOPS, EDTA, CaCl2 2H2O, pyruvate, PBS
sachets, Tween20, and bovine serum albumin were purchased from
Sigma (Poole, UK); MgSO4 7H2O, NaOH, and NaH2PO4 H2O were pur-
chased from VWR (Leicestershire, UK); and bradykinin was purchased
from Tocris (Bristol, UK). The cellular dyes Hoechst 33342 (H3570), PI
(P1304MP), DAPI (D3571), and AF-633 (A30634) were purchased from
ThermoFisher Scientific (Paisley, UK), phalloidin-TRITC from Sigma-
Aldrich (Dorset, UK), and fluo-8 AM from AAT Bioquest (Stratech,
Newmarket, UK). Paraformaldehyde was purchased from Electron
Microscope Sciences (Hatfield, PA, USA).
2.11 Statistics
Statistical analysis was performed using GraphPad Prism software (ver-
sion 8, GraphPad Software, La Jolla, USA), where P < 0.05 was consid-
ered significant. All specimens collected were analysed and no
experimental data were excluded from the study. Formal statistical com-
parisons on our unpaired data first tested for Gaussian distributions
(D’Agostino and Pearson omnibus normality test), which confirmed that
for all comparisons non-parametric tests should be used with no as-
sumption of equal standard deviation. Subsequently, two groups were
compared with two-tailed Mann–Whitney tests, and groups of three or
more with Kruskal–Wallis tests and Dunn’s post-test. For this analysis
values are the mean ± SEM. To correlate MT results with synthetic
markers in r-SMCs or with other variables, univariable and multivariable
linear regression models were run using R (version 3.6.0, https://www.R-
project.org/) and jtools (version 2.0.1, https://cran.r-project.org/pack
age=jtools), and as indicated, adjusted for any known risk factors (Model
A: sex, type of valve disease, hypertension, hypercholesterolaemia, and
smoking history) and medications (Model B: statins, diuretics, Ca2þ chan-
nel blockers, beta-blockers, aspirin, anticoagulants, and angiotensin-con-
verting-enzyme-inhibitors). Multiple regression linear models were
obtained after a forward/backward stepwise selection process with AIC
as the selection criterion for the final model. Analysis for a global valida-
tion of the linear model assumptions as well as separate evaluations of
skewness, kurtosis, link function, and heteroscedasticity were tested us-
ing R (package, lmSupport; function, modelAssumptions) and all were
found to be acceptable. Original data points are presented as scatter
plots where possible, and these data were tested for Gaussian distribu-
tions (D’Agostino and Pearson omnibus normality test or Shapiro Wilk
test). For ease of visualization, the mean ± SEM are shown on the scatter
plots. The inclusion of all arteries, including those that did not develop
MT, meant the 88 MT values for h-RA-IMCA data were not normally dis-
tributed, so we report the median with lower 95% and upper 95% confi-
dence intervals in the figure legends using the format [median, LCI, UCI].
Other data were normally distributed and, where reported, the median
was shown as [median].
3. Results
This study reports the outcomes of assessing pressure-induced MT for
each IMCA studied from every biopsy transported to the laboratory,
without exclusion. We commenced our succession of protocols using
surgically provided biopsies (h-RA-IMCAs) (Figure 1A–C) and later ex-
tended these to include (i) RA and LV IMCAs from organ donor proce-
dures (hOD-RA-IMCAs and hOD-LV-IMCAS); and (ii) porcine IMCAs
(p-RA-IMCAs and p-LV-IMCAs).
3.1 MTof h-RA-IMCAs
Following our assessment of MT using confocal microscopy (SMC Test
1) (Figure 2A), all the subsequent experimental protocols were success-
fully performed using the cannulated arteries. On 26 occasions, multiple
h-RA-IMCAs were dissected from the same biopsy/patient, allowing an
intra-sample comparison of MT. We found that measurements were
consistent across multiple arteries from the same biopsy, thus suggesting
that each artery faithfully representing the condition of the patient sam-
ple (Figure 2B). The average pressure-induced MT in h-RA-IMCAs was
14.5 ± 1.5% (n = 88, from passive diameter, 135 ± 4 mm) (Figure 2C) .
About 56% of h-RA-IMCAs developed >_10% tone (24.3 ± 1.5% tone, n
= 49) and, from this vaso-reactive group, EC-dependent dilation to bra-
dykinin was established (pEC50 = 8.6 ± 0.1, n = 33) (Figure 2D). A univari-
able analysis showed a significant, but weak, correlation of poor MT with
ageing (P = 0.038) (Figure 2E); however univariable and multivariable
models adjusted for other risk factors and medications showed no clear
correlation of disease circumstance with poor MT (Supplementary ma-
terial online, Figure S1 and Table S1).
3.2 Tissue architecture and 3D cell
alignment in h-RA-IMCAs
Ultrastructural evaluation of h-RA-IMCA SMC density and orientation
(SMC Test 2) (Figure 3A) showed the typical circumferentially orientated
SMCs responsible for radial contraction (r-SMCs). Shifting the focal
plane towards the endothelium revealed an additional 3D layer of longi-
tudinal/spiral SMCs bridging r-SMCs and ECs, which we name ‘longitudi-
nal-SMCs’ (l-SMCs) (Figure 3A), before reaching the ECs. l-SMCs were
visible in transmitted light (Figure 3B), and slight movement of the wall in
the longitudinal axis (5–10 mm) could be observed and measured within
the confines of fixed position pipettes at each end of arteries (Figure
3B–E). This inner layer of l-SMCs (Figure 3F) was therefore contractile in
some arteries. Evaluation of arterial motion during measurements of MT
or vasoconstrictor responses to isotonic KCl revealed that 51.1% of h-
RA-IMCAs visibly contracted solely along the circumferential/radial axis;
30.7% additionally contracted along a longitudinal/twisting axis; 5.7%
only moved in a longitudinal/twisting axis; and 12.5% were completely
vaso-inactive (Figure 3G). Overall, the r-SMC and l-SMC layers appeared
linked together into a ‘concertina-type’ 3D tissue architecture within the
h-RA-IMCA (Figure 3H).
3.3 Spatial 3D resolution of ECs, l-SMCs,
and extracellular matrix
A longitudinal internal elastic lamina (IEL) was observed abluminal to the
endothelial monolayer in p-RA-IMCAs (Supplementary material online,
Movie S1). In h-RA-IMCAs, a high density of elastin could also be seen be-
tween and beyond SMCs (Figure 4A and Supplementary material online,
Figure S2). Nevertheless, the ability of arteries to distend to luminal pres-
sure did not predict whether MT could develop (Supplementary








































..material online, Figure S2D). TEM revealed h-RA-IMCAs that developed
MT had uniformly arranged r-SMCs, whereas the spatial arrangement of
r-SMCs in those that did not develop tone was more intermittent. l-
SMCs were identified, making multiple cell–cell contacts with r-SMCs
and/or ECs (SMC Test 3) (Figure 4A) (Patients 1–3 and 6). In the same h-
RA-IMCAs, the extent of MT was generally associated with EC function
(Figures 4B and C). To extend our observations, the 3D spatial structure
and cell–cell contacts in 3 of the 8 h-RA-IMCAs were revealed using se-
rial block face-scanning electron microscopy (SBF-SEM) (Supplementary
material online, Figure S3A and Movies S2–S4). Combining all imaging
approaches, we found that l-SMCs were always evident as small groups
or ‘reefs’ and were present in 66% of h-RA-IMCAs (n = 32). Of the 32 ar-
teries within which the arrangement of SMCs was imaged, there was no
clear link between the presence of l-SMCs and the ability to develop MT.
The developed MT was similar in RA-IMCAs with (11.3 ± 3.8% tone, n =
21) or without l-SMCs (8.9 ± 2.8% tone, n = 11).
3.4 Cell viability and Ca26 signalling in
h-RA-IMCAs
Measurements of cell viability in h-RA-IMCAs indicated that there was
no correlation (P = 0.232) between the extent of MT and percentage of
viable r-SMCs (SMC Test 4, Supplementary material online, Figure S4A–
C). Even in IMCAs with no MT, 70 ± 6% (n = 7) of cells were viable. ECs
were also predominantly viable (83 ± 4%, n = 12) (Supplementary mate-
rial online, Figure S4A and B), and able to drive EC-dependent dilation
(Supplementary material online, Figure S4D). Ca2þ indicator dyes further
defined viable cells and each cell type (SMC Test 5, Supplementary mate-
rial online, Figure S4E). Analysis of Ca2þ indicator fluorescence responses
over time showed h-RA-IMCAs with poor MT (5.6 ± 2.4%, n = 12, in-
cluding 7 with no MT) increased intracellular Ca2þ to isotonic KCl and
caffeine, and ECs responded to bradykinin (Supplementary material on-
line, Figure S4F). This demonstrates that viable SMCs with functional
voltage-dependent Ca2þ channels and RyRs do not necessarily develop
MT. Finally, to test water barrier function, hydraulic conductivity meas-
urements indicated no difference between h-RA-IMCAs with MT (44 ±
11 10-7cm/s/cmH2O, 29 ± 5% tone, n = 5) and those with <10% MT
(43 ± 710-7cm/s/cmH2O, 3 ± 1%, n = 8).
3.5 Lack of MT correlates with synthetic
phenotype in h-RA-IMCA r-SMCs
The disconnect between contractile dysfunction in SMC Test 1 and via-
bility (SMC Tests 2–5) required another explanation for the lack of MT
in almost 50% of h-RA-IMCAs. The evidence pointed downstream of
Ca2þ handling, so SMC phenotype was interrogated (SMC Test 6).
Figure 2 Vaso-reactivity of human and porcine RA-IMCAs. (A) Micrograph of an isolated, cannulated and pressurized h-RA-IMCA and p-RA-IMCA with
MT. (B) The MT developed in h-RA-IMCAs within each patient biopsy was consistent, but varied between biopsies (n = 26; non-parametric Kruskal–Willis
test with Dunn’s post-test). If an intra-biopsy mean MT was >_10% it was different to the mean for Patient 1. (C) Summary of percentage MT in h-RA-IMCAs
[(12.5%,8.6,16.3), n = 88] and p-RA-IMCAs [(25.3%), n = 39]. (D) Concentration-dependent vasodilation to bradykinin (BK), assessed from developed MT,
in h-RA-IMCAs (n = 33) and p-RA-IMCAs (n = 19). (E) Relationship between patient age and MT (n = 88, red circles indicate 12 patients on calcium channel
blockers). One-way ANOVA in (B), and linear regression in (E). Further details regarding patient demographics and medications available in Table 1 and
Supplementary material online, Figure S1A–D.
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Figure 3 Longitudinally aligned medial SMCs (l-SMCs) can cause longitudinal movement in h-RA-IMCAs. (A) Confocal micrographs from a cannulated
and pressurized h-RA-IMCA. The confocal z-stack reveals circumferentially arranged r-SMCs and l-SMCs stained with phalloidin, and further towards the lu-
men in the same artery, Kþ-channel (KCa3.1) label of ECs; bar =20 mm. (B) Micrograph of an isolated, cannulated and pressurized h-RA-IMCA with MT, with
cannulating pipettes visible. Careful inspection of the wall reveals a diagonally orientated sheet or ‘reef’ of l-SMCs (white arrows); bar =122 mm. (C, D) The
artery in (B) was treated with 1 mmol/L BK to generate a time-course of dilation (C). (D) Frame-by-frame analysis of the motion revealed longitudinal (L)
movement of the wall before the onset of radial movement; red arrowheads in (C) refer to images in (D), white crosses refer to movement; bars =50 mm.
After a few seconds, the wall began to dilate radially with an ultimate diagonal ‘concertina-type’ twisting effect. Based on this motion, the MT in this artery
was classified as ‘RþL’ constriction. (E) The magnitude of longitudinal motion was assessed for every artery (n = 88). Only arteries where clear longitudinal
movement of >_5 mm were considered RþL. (F) Schematic depiction of the cellular arrangement. (G) Most h-RA-IMCAs developed MT in a radial manner
(R, n = 38), including some with additional longitudinal movement (RþL, n = 23), and one artery with clear longitudinal movement (L) but no change in diam-
eter. The vasoconstrictor tone to isotonic 45 mmol/L KCl (KCl) was assessed in a subset of arteries with MT (red triangles, n = 13) and without MT (grey tri-
angles, n = 27). Non-parametric unpaired t-test, Mann–Whitney post-test. (H) Schematic depicting the dilated state and the two most commonly observed
modes of SMC contraction, either R or RþL.‡, Confocal z-stack through the wall of the IMCA.






























..Immunolabel for the contractile proteins SM-MHC and a-SMA was
compared to the synthetic phenotypic markers caldesmon (l-caldesmon
isoform)38 and vimentin. A gross heterogeneity in expression of SM-
MHC or a-SMA relative to caldesmon was observed in both r-SMCs
and l-SMCs, with individual SMCs often differing from neighbour SMCs
(Figure 5A and Supplementary material online, Movie S6). A similar profile
was observed with SM-MHC or a-SMA relative to vimentin, although
vimentin also labelled ECs and fibroblasts (Figure 5B). This cell-specific
immunolabelling also confirmed the presence of l-SMCs between the
ECs and r-SMCs (Figure 5A and C). Poor MT was associated with caldes-
mon or vimentin expression in the r-SMC cells (Figures 5D and E) in this
59–70 years old group of patients (n = 8, P = 0.003).
3.6 MT, tissue architecture, cellular
phenotyping, and function of hOD-LV-
IMCAs
To ascertain the relevance of our findings using h-RA-IMCAs to h-LV-
IMCAs, and given it was unethical and hence not possible to obtain large
ventricular biopsies from cardiac surgery procedures in Bristol, we
sourced a small number of human LV (and RA) biopsies (1 cm2) from
participants subjected to organ donor (hOD) procedures in Newcastle.
Using the same methodological approach, we were able to obtain a small
number of human atrial IMCAs (hOD-RA-IMCAs) and ventricular
IMCAs (hOD-LV-IMCAs). The aim here was to compare SMC Test 1 to
SMC Test 6 to check the validity of our finding that MT related to SMC
phenotype, and could be translated across heart chambers. hOD-IMCAs
were successfully cannulated and each developed good MT (>_10%) in
response to 80 mmHg luminal pressure (Figures 6A and B). When
Figure 4 h-RA-IMCA MT and EC-dependent vasodilation linked to high resolution structure. (A) TEM from cannulated and pressurized h-RA-IMCAs.
Images show multiple sites of contact between ECs and SMCs (r-SMC and l-SMC). Severely damaged ECs (ghost cells) remained in close contact with adja-
cent ECs. Inflammatory cell; bar =1 mm. l-SMCs, when present, are always found between the r-SMC and EC layers. SEM 1–3, indicates h-RA-IMCAs proc-
essed for SBF-SEM (Supplementary material online, Figure S3A). The level of MT (B) and vasodilation to 10 nM BK (C) in each h-RA-IMCA subsequently
processed for EM (Patients 1–8) reveals arterial ultrastructure is markedly altered in arteries without MT, with extensive thickening of the elastin layer sepa-
rating the ECs and SMCs (IEL).
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Figure 5 The contractile phenotype of r-SMC in h-RA-IMCAs and p-RA-IMCAs correlates with vasomotor function. (A and B) Confocal micrographs
from cannulated and pressurized IMCAs. Each artery was imaged at two focal planes: towards the outer wall to image r-SMCs, and towards the lumen to im-
age l-SMCs or ECs [indicated in (C)]. (A) r-SMC and l-SMCs labelled for a-SMA and caldesmon (see Supplementary material online, Movies S6 and S7). Note
the heterogeneity of a-SMA labelling in h-RA-IMCA l-SMC (arrowheads). (B) Cell labelling for SM-MHC and vimentin. Vimentin was sparse in r-SMC, while
homogeneous in both ECs (also indicated by von Willebrand Factor, vWF) and perivascular cells (fibroblasts). (A and B) The labelling profile for each protein
is indicated by the fluorescence intensity (F, arbitrary units, a.u.) of a line drawn through the image at the point indicated by the white dashed lines. Bar =20
mm. Representative of three human and three porcine arteries. (D and E) Percentage of r-SMC with relatively stronger expression of synthetic markers (cal-
desmon or vimentin) than contractile markers (SM-MHC or a-SMA) within the cytoplasm of the cell plotted against the percentage of developed MT gener-
ated in each artery (D); and in the same arteries, the percentage vasoconstriction to 45 mmol/L isotonic KCl (E). Open symbols, individual data points;
closed symbols, mean data; red dots, SM-MHC antibody. Linear regression through individual data points, with 95% confidence interval, in (D).‡, Confocal
z-stack through the wall of an IMCA.





















































comparing h-RA-IMCAs exhibiting >_10% MT in Figure 2 to hOD-RA-
IMCAs and then to hOD-LV-IMCAs, the level of MT development was
remarkably similar (Figure 6B). Human OD-LV-IMCAs had high levels of
SM-MHC in r-SMCs (Figure 7A, orientation Figure 7B), with similar pro-
files of expression between heart chambers (Figure 7C). We were also
able to confirm that l-SMCs are present in both heart chambers, regard-
less of human tissue source (Figure 7A and D).
3.7 Porcine IMCAs as a relevant preclinical
model
SMC Tests were also performed using porcine RA-IMCAs. p-RA-IMCAs
developed >_10% MT (from passive diameter 202 ± 12 mm, n = 39), with
an average of 28.2 ± 1.7% MT (SMC Test 1) (Figure 2C). EC-dependent
dilation to bradykinin was 100 more sensitive than in h-RA-IMCAs
(pEC50 = 10.7 ± 0.1, n = 19) (Figure 2D). Combined data from confocal
fluorescence microscopy images showed that 82% of p-RA-IMCAs (n =
22) featured l-SMCs (one example in Figure 5A), which were confined to
sub-sections of the IMCAs (Supplementary material online, Figure S3B).
Despite this high incidence of l-SMCs, 95% of p-RA-IMCAs (n = 39) fea-
tured radial contraction, with no detectible longitudinal/twisting motion.
The porcine arterial SMCs and ECs showed changes in cytosolic Ca2þ
similar to that observed in h-RA-IMCAs (SMC Test 4, Supplementary
material online, Figure S4F). The hydraulic conductivity of p-RA-IMCAs
was 13.9 ± 3.810-7cm/s/cmH2O (n = 4).
The co-expression of SM-MHC or a-SMA and caldesmon in p-RA-
IMCAs differed between r-SMCs and l-SMCs. r-SMCs from p-RA-
IMCAs uniformly expressed SM-MHC and a-SMA but almost no cal-
desmon; and while l-SMCs also expressed SM-MHC and a-SMA, cal-
desmon was clearly evident (SMC Test 6) (Figure 5A and
Supplementary material online, Movie S7). A similar profile to caldes-
mon was observed with vimentin in r-SMCs (Figure 5B); the major
difference being that vimentin was not observed in l-SMCs, despite
clear labelling with SM-MHC or a-SMA and positive detection of
vimentin in ECs and fibroblasts (n = 3). In p-RA-IMCAs, robust MT
and constriction to isotonic KCl were associated with almost no ex-
pression of caldesmon or vimentin in r-SMCs (Figure 5D and E).
Univariable analysis of the combined human and porcine RA-IMCA
data showed a significant correlation of synthetic markers in r-SMCs
with poor MT (P < 0.001) (Figure 5D).
Finally, when these phenotypic data were plotted against developed
MT in both species, cardiac chambers and sources of human tissue, the
relative expression of caldesmon and SM-MHC in r-SMCs strongly cor-
related with poor MT (P < 0.001) (SMC Test 6) (Figure 7).
4. Discussion
The key finding of this study is the demonstration that poor MT ob-
served in h-IMCAs isolated from non-ischaemic human myocardium is
associated with a synthetic phenotype in still viable r-SMCs. As such
these usually discarded arteries form a novel model for studying coro-
nary microvascular contractile dysfunction. In addition, by using organ
donor tissue, we validate the findings obtained from h-RA-IMCAs and
extend to IMCAs from the human left ventricle. The trends in data were
supported by atrial and ventricular arteries studied from pigs, in doing so
providing a clinically relevant large animal model to study microvascular
function. Overall, the comparisons of RA- vs. LV-IMCAs in humans and
in pigs showed equivalent links between MT and the synthetic phenotype
of SMCs, 3D tissue architecture, and cell viability.
Figure 6 Summary of MT development in ex vivo human and porcine IMCAs isolated from RA appendages and the endocardial surface of left ventricles.
(A) Micrograph of an isolated, cannulated and pressurized human organ donor (OD)-LV-IMCA and porcine LV-IMCA with MT. (B) When data from the 88
human RA-IMCAs were divided into two groups such that those with <10% MT were shown separately [(0.0%,0.0,0.9), n = 39], the human RA-IMCA group
with >_10% MT [(23.2%), n = 49] appeared remarkably similar to the organ donor [(27.9%), n = 3, (26.2%), n = 4] and porcine [(25.3%), n = 39, (21.6%), n =
3] RA- and LV-IMCA groups, respectively. The human RA-IMCA >_10% group represents human RA-IMCAs generally used by researchers for vaso-reactiv-
ity studies, whereas the human RA-IMCA <10% group represent RA-IMCAs with microvascular contractile dysfunction. The mean±SEM values are pro-
vided for each group. Note that, all arteries were studied ex vivo under the same conditions by the same research team. Data from Figure 2C are included, for
comparison.

















RA-IMCAs provide the primary source of human ex vivo live-cell coro-
nary microvascular studies. To date no studies have established why MT
does not develop in a subset of IMCAs, these unresponsive arteries are
usually discarded or not mentioned.23–25 The precious nature of these
biopsies means in some cases vasoconstrictor agonists is employed to
augment weak MT, but arterial viability is not systematically reported.28
These approaches are justified when the focus of the study is based on
vaso-reactivity. However, in this study, we intentionally used all IMCAs
to identify determinants of poor MT, highlighting the potential relevance
of this subset to coronary microvascular dysfunction.
The time delay from tissue harvesting to ex vivo testing was minimized
for all human and porcine biopsies (h-RA-IMCAs < p-IMCAs hOD-
Figure 7 The contractile phenotype of r-SMC in both human and porcine IMCAs correlates with vasomotor function. (A) The LV-IMCAs shown in Figure
6A were labelled for SM-MHC and caldesmon and r-SMCs, l-SMCs and ECs imaged (schematic in B). The position of ECs was confirmed using label for vWF.
The labelling profiles for each protein are indicated by the fluorescence intensity (F, arbitrary units, a.u.) of a line drawn through the image at the point indi-
cated by the white dashed lines. Representative of 4 human OD and 11 porcine LV-IMCAs. (C) Percentage of r-SMC with relatively stronger expression of
caldesmon than SM-MHC within the cytoplasm of the cell plotted against the percentage developed MT in each artery. All data using this combination of
markers is shown from both atrial and ventricular biopsies from both species and heart chambers, for comparison. In general, the human OD-LV-IMCAs
had more heterogeneous labelling of contractile markers than the pig LV-IMCAs despite similar levels of developed MT (see Figure 6). Of 4 human OD-LV-
IMCAs, 3 had visible l-SMCs (75%), and of 11 porcine LV-IMCAs, 8 had visible l-SMCs (73%). (D) Percentage of cells with clear caldesmon expression in l-
SMC plotted against percentage of cells with expression in r-SMCs (n = 3 human, and n = 8 porcine LV-IMCAs). Open symbols, individual data points; closed
symbols, mean data. Linear regression through individual data points, with 95% confidence interval, in (C).‡, Confocal z-stack through the wall of an IMCA.

































































































IMCAs). We are confident that the observed variations in h-RA-IMCA
MT, phenotype, function, and 3D architecture are unlikely to arise ex
vivo. The lack of MT in 44% of h-RA-IMCAs/patients was not due to cell
death or poor viability when assessed by live-dead staining or by the abil-
ity to raise cytosolic [Ca2þ] in response to vasoconstrictors. All IMCAs
derived from healthy human (including organ donors) or pig developed
an average of 25% MT following equivalent methodological
approaches and timing.
The key finding of this study was the association between the lack of
MT in IMCAs and the presence of SMCs with a synthetic phenotype.
Defining the best markers to discriminate between synthetic and con-
tractile SMCs is still ongoing in the literature.1,2,39–42 This study shows
the ratio of caldesmon to SM-MHC is a combination that fits well with
the accepted categorization;2 especially since vimentin also labels ECs
and fibroblasts, while a-SMA also labels immature or de-differentiated
SMCs. It was not necessary to use a selective l-caldesmon antibody; the
relative expression of both caldesmon isoforms, when combined with
SM-MHC label, very clearly corresponds with SMC contractile function
and is therefore highly useful in itself to discriminate between SMC phe-
notypes. Future studies could use single-cell nuclear-SEQ or spatial tran-
scriptomics to establish whether other markers2,43,44 could also serve as
discriminators between synthetic and contractile SMCs within IMCAs
subjected to a matched functional assessment of MT development. Our
finding that the developed MT in an IMCA from a given biopsy closely
represents other IMCAs could aid this difficult question. Ultimately the
precise molecular switches to a synthetic phenotype should be identi-
fied,45 alongside treatments aimed at preserving key extracellular pro-
teins and peptides.2
Human RA-IMCAs had dense layers of elastin and collagen between
cells, more so than in porcine RA-IMCAs, in keeping with similar findings
by others in human and porcine parietal pericardial micro-arteries.46,47
While we showed no clear relationship between percentage MT and the
ability for passive distension, a sub-group of arteries were less able to
passively increase diameter to raised luminal pressure. We did not assess
the thickening of the extracellular matrix in these arteries. Therefore, we
propose that in future experiments, routine measurements of passive
distention should be performed, and arteries that are ‘inflexible’ are con-
sidered a separate group, not suitable for functional analysis. We also
propose that when feasible, fluorescence-based live-cell imaging of the
thickening of the extracellular matrix should also be performed,46,47 and
matched to contractile function. Higher resolution imaging using EM has
been performed previously in cardiac IMCAs.48–50 A distinct advantage
of our approach was we fixed the h-RA-IMCAs at physiological luminal
pressure following MT measurement. This not only allowed us to image
detailed 2D and 3D structure to MT, but also provided novel insights
into the arrangement and shape of SMCs as radial or longitudinal along
the artery axis. The l-SMCs in the sub-endothelial layer of IMCAs is con-
sistent with reports in large epicardial coronary arteries.51,52 We found
that the l-SMCs intertwine and integrate with the r-SMCs, raising the
question as to their source and whether there are parallels with patho-
logical processes observed in epicardial large coronary arteries53–56 or
vein grafts,57,58 where recruited SMCs migrate to form an intimal layer.
Comparative evaluations confirmed that atrial and ventricular
IMCAs from healthy humans and pigs are equivalent in terms of MT,
cell viability and function, phenotypic profile of SMCs, and IMCA 3D
architecture. We also noted that if the cut-off for poor MT was set
at <10% the average MT in h-RA-IMCAs was similar to hOD-RA-
IMCAs and hOD-LV-IMCAs, indicating a valuable index for future
studies.
4.1 Study limitations
A major limitation of this field is not being able to establish the myogenic
reactivity of LV-IMCAs in patients with heart disease either in vivo or ex
vivo and, specifically relevant to this study, those with heart valve disease.
This cohort of patients underwent voluntary, recovery surgery, and suffi-
ciently large LV biopsies were not ethically possible to harvest. While it
is possible to demonstrate that coronary flow reserve is compromised
in patients with heart valve disease,59 this cannot be precisely linked to
the myogenic reactivity of LV-IMCAs either in vivo or ex vivo. Therefore,
we have made every attempt to address this, albeit indirectly, by demon-
strating (i) the RA-IMCAs from organ donors have similar MT develop-
ment and phenotypic profiles to the subset of RA-IMCAs from valve
surgery patients that developed >_10% MT; (ii) in the same organ donor
patients, the myogenic reactivity of the LV-IMCAs was the same in their
RA-IMCAs; and (iii) the MT in porcine IMCAs was the same as organ do-
nor IMCAs. Therefore, we can only speculate that the subset of heart
valve disease patients with <10% MT in their RA-IMCAs had similarly af-
fected ventricular microvascular arteries. This is clearly an area that war-
rants much future investigation, the first step being to match
measurements of coronary flow reserve in vivo to RA-IMCA myogenic
reactivity ex vivo in an intra-patient context. The ability to routinely ob-
tain RA-IMCAs for ex vivo study could then provide a clinically useful sur-
rogate biomarker for ventricular microvascular dysfunction in these
patients.
5. Conclusions
In conclusion, our data suggest that >40% of h-IMCAs from patients un-
dergoing surgery for valve disease, but without severe coronary disease
or pulmonary hypertension, are affected by poor MT and that this finding
is strongly associated with a synthetic phenotype of viable r-SMCs.
These findings may offer an insight on coronary microvascular dysfunc-
tion that may predate the development of clinically indicated heart dis-
ease, such as heart failure and warrant further investigations.
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Translational perspective
Vasoconstriction of micro-arteries to luminal pressure is a fundamental control on blood flow within the coronary microcirculation, but MT cannot
be independently measured in vivo. Patients with poor MT would not only have dysregulated microvascular blood flow, but the superimposed prob-
lem of limited scope for vasodilation, and hence poor coronary flow reserve. By moving to ex vivo studies, our finding that >40% of heart valve dis-
ease patients have arteries with poor MT identifies an ex vivo model to study human microvascular contractile dysfunction and will stimulate
research to assess associations with other biomarkers and their impact on long-term patient outcome. Furthermore, without the routine ability to
study the human ventricular microcirculation ex vivo, it is a key to improve in vivo imaging technology to screen and characterize patients at risk and
establishing medicinal strategies to ameliorate these.
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